Paul Tudor Jones Arcellx, Inc. Transaction History
Tudor Investment Corp Et Al
- $44 Billion
- Q2 2025
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Arcellx, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 23,197 shares of ACLX stock, worth $1.97 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,197
Previous 4,200
452.31%
Holding current value
$1.97 Million
Previous $275,000
455.27%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ACLX
# of Institutions
219Shares Held
49.1MCall Options Held
245KPut Options Held
885K-
Paradigm Biocapital Advisors LP New York, NY4.65MShares$395 Million14.29% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.94MShares$336 Million0.0% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$319 Million20.45% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$299 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.04MShares$258 Million4.37% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3.73B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...